alpha-aminopyridine has been researched along with Meningeal Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ma, MJ; Mekhail, TM; Parker, JV; Yuan, C | 1 |
| Buffoni, L; Pellerino, A; Rudà , R; Soffietti, R | 1 |
| Adetchessi, T; Barlier, A; Chinot, O; Defilles, C; Dufour, H; Enjalbert, A; Figarella-Branger, D; Fuentes, S; Germanetti, AL; Graillon, T; Lisbonis, C; Metellus, P; Mohamed, A; Roche, PH | 1 |
3 other study(ies) available for alpha-aminopyridine and Meningeal Neoplasms
| Article | Year |
|---|---|
Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report.
Topics: Adolescent; Aminopyridines; Anaplastic Lymphoma Kinase; Brain Neoplasms; Crizotinib; Female; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Meningeal Neoplasms; Myofibroblasts; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sarcoma; Sulfones | 2017 |
Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Spinal Cord Neoplasms; Sulfones; Treatment Outcome | 2019 |
Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Cell Cycle; Cell Survival; Drug Therapy, Combination; Everolimus; Female; Humans; Imidazoles; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Morpholines; Neurofibromin 2; Octreotide; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Receptors, Somatostatin; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |